Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 18;14(1):15.
doi: 10.1186/s13048-020-00755-z.

Effects of exogenous adiponectin supplementation in early pregnant PCOS mice on the metabolic syndrome of adult female offspring

Affiliations

Effects of exogenous adiponectin supplementation in early pregnant PCOS mice on the metabolic syndrome of adult female offspring

Meng Zuo et al. J Ovarian Res. .

Abstract

Objective: PCOS is a heterogeneous endocrine disorder with both reproductive and metabolic abnormalities. At present, PCOS has been confirmed to have a certain genetic background. Compared with healthy women, the vast majority of PCOS patients have hyperandrogenemia, and this excessive androgen exposure during pregnancy may affect the development of female fetuses. The aim of the current study was to investigate the effect of adiponectin intervention during early pregnancy of obese mice with PCOS on the metabolic phenotype of adult female offspring.

Methods: After the PCOS model was established, C57BL/6J mice were divided into maternal-control, maternal-PCOS, and maternal-PCOS + APN groups. DHEA-induced PCOS mice were supplemented with adiponectin (10 mg/kg/day) in the early pregnancy in order to eliminate adverse hormone exposure and then traced for endocrine indicators in their adult female offspring, which were observed for metabolism syndrome or endocrine disturbance and exhibited the main effects of APN. To further explore the underlying mechanism, the relative expressions of phosphorylated AMPK, PI3K, and Akt were detected in the ovaries of offspring mice.

Results: The serum testosterone level of the maternal-PCOS + APN group in early pregnancy was significantly lower than that of the maternal-PCOS group (p < 0.01). The serum testosterone level in the offspring-PCOS + APN group was significantly lower than in the offspring-PCOS group (p <0.05), the diestrus time characterized by massive granulocyte aggregation in the estrus cycle was significantly shorter than in the offspring-PCOS group (p<0.05), and the phenotypes of PCOS-like reproductive disorders and metabolic disorders, such as obesity, insulin resistance, impaired glucose tolerance, and hyperlipidemia, were also significantly improved in the offspring-PCOS + APN group (p < 0.05). Compared with the control group, the expression levels of phosphorylated AMPK, PI3K, and Akt in the offspring-PCOS group were significantly decreased (p < 0.05), while those in the offspring-PCOS + APN group were significantly increased (p < 0.05).

Conclusions: APN intervention in early pregnancy significantly reduced the adverse effects of maternal obesity and high androgen levels during pregnancy on female offspring and corrected the PCOS-like endocrine phenotype and metabolic disorders of adult female offspring. This effect may be caused by the activation of the AMPK/PI3K-Akt signaling pathway in PCOS offspring mice.

Keywords: Adiponectin; Metabolic syndrome; Offspring; Polycystic ovary syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Schematic representation of the different experimental groups: offspring-control group (n = 6; maternal-control group offspring, SD); offspring-PCOS group (n = 6; maternal-PCOS group offspring, SD); offspring-PCOS + APN group (n = 6; maternal-PCOS + APN group offspring, SD)
Fig. 2
Fig. 2
Establishment of the PCOS model. a Changes in the active testosterone expression in mice after an effective dose of DHEA stimulation; b significant differences in the body weight between the control and model groups; c ovarian tissue sections were prepared from control or model mice for H&E staining. Antral follicle (AF), preovulatory follicle (PF), cystic follicle (CF), granulosa cell (GC), and corpora lutea (CL) were annotated. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus untreated control mice. Data are indicated as mean ± SD (n = 3)
Fig. 3
Fig. 3
Hormone levels in trunk blood measured by ELISA for each group. Maternal (a) and offspring (b) serum adiponectin and testosterone levels were determined. (c) Representative estrous cycles of six mice per group during 20 consecutive days. (d) Representative photomicrographs of ovaries stained with hematoxylin-eosin of control, PCOS, and PCOS + APN mice. Antral follicle (AF), preovulatory follicle (PF), cystic follicle (CF), granulosa cell (GC), and corpora lutea (CL) were annotated. *p < 0.05, **p < 0.01
Fig. 4
Fig. 4
Adiponectin improves serum lipid profiles and the glucose metabolism of PCOS offspring mice. Antidiabetic effect of adiponectin on PCOS offspring mice: BW (a), basal blood glucose (b), IPGTT and AUC levels (c), IPITT and AUC levels (e), serum insulin (d), and HOMA-IR index (f). g TC, TG, HDL-C, and LDL-C levels of serum that was obtained from 13-week-old mice of each group
Fig. 5
Fig. 5
Effects of adiponectin on AMPK, PI3K, and Akt phosphorylation expression in PCOS offspring mice. a Immunoblotting of protein extracts from ovarian tissues of PCOS offspring mice treated with adiponectin during the embryonic phase in comparison with control and untreated PCOS offspring mice. b-d Content of mRNA of phosphorylated AMPK, PI3K, and Akt of mice of each group

Similar articles

Cited by

References

    1. Jayasena CN, Franks S. The management of patients with polycystic ovary syndrome. Nat Rev Endocrinol. 2014;10(10):624–36. doi: 10.1038/nrendo.2014.102. - DOI - PubMed
    1. Teede HJ, Misso ML, Costello MF, et al. International PCOS Network Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364–79. doi: 10.1016/j.fertnstert.2018.05.004. - DOI - PMC - PubMed
    1. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270–84. doi: 10.1038/nrendo.2018.24. - DOI - PubMed
    1. Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome. Lancet. 2007;370:685–97. doi: 10.1016/S0140-6736(07)61345-2. - DOI - PubMed
    1. Fraissinet A, Robin G, et al. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome. Hum Reprod. 2017;32(8):1716–22. doi: 10.1093/humrep/dex239. - DOI - PubMed

LinkOut - more resources